Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of EU, US, and Japan-sourced Apremilast
NCT04811573Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apremilast in psoriasis (10 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of Apremilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point, Area Under the Concentration-time Curve of Apremilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity and 1 more. Started Mar 2021; status: terminated.
02
Drugs
apremilast
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT04811573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04811573.